Hi, today we are going to talk about Proteostasis Therapeutics and its current landscape.

Proteostasis Therapeutics is poised to receive increasing attention from the market as relevant events are taking place. Despite the fact that the company had reported positive data from a phase 2 clinical trial testing its triple-drug combination in patients with cystic fibrosis, investors crushed the company shares, seeing that its results were below the reported by Vertex Pharmaceuticals similar product named Trikafta. Now it's up to Proteostasis Therapeutics to find a solution to improve its results and maybe rebound because it didn't, would mean that the company will have made a bad investment that could severely cost to its next results.

Thank you for reading and leave your comments if you like.

To have access to our exclusive contents, join the Traders Heaven today! Link Below.

Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.


The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.